Showing 1791-1800 of 4063 results for "".
- Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapyhttps://modernod.com/news/glaukos-announces-commencement-of-phase-2-corneal-health-clinical-program-for-third-generation-ilink-therapy/2480696/Glaukos announced that it has commenced a phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Glaukos’ iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activa
- New 2-Year Data for Genentech’s Vabysmo and Susvimo Show Potential of Fewer Treatments for People With Wet AMD and DMEhttps://modernod.com/news/new-2-year-data-for-genentechs-vabysmo-and-susvimo-reinforce-potential-to-maintain-vision-with-fewer-treatments-for-people-with-wet-amd-and-dme/2480631/Genentech announced that new 2-year data from its phase 3 studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be presented at Angiogenesis, Exudation and Degeneration 2022 on February 12. These longer-term r
- Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitishttps://modernod.com/news/tarsus-completes-enrollment-for-the-pivotal-phase-3-saturn-2-trial-of-tp-03-to-treat-demodex-blepharitis/2480610/Tarsus Pharmaceuticals announced it has completed enrollment of Saturn-2, the company’s second pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with Demodex blepharitis and executed a $175 million credit facility with Hercules Capital and Silicon
- Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Modelhttps://modernod.com/news/aldeyra-therapeutics-announces-publication-of-phase-2-clinical-trial-of-reproxalap-in-allergen-chamber-model/2480608/Aldeyra Therapeutics announced that results from the randomized, double-masked, vehicle-controlled, crossover phase 2 clinical trial of reproxalap in an allergen chamber model have been published in the peer-reviewed journal Clinical Ophthalmology.1 Reproxalap, an
- Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trials for Presbyopia and Dry Eye Diseasehttps://modernod.com/news/glaukos-announces-first-patient-enrolled-in-phase-2-clinical-trial-for-presbyopia/2480564/Glaukos announced that it has enrolled the first patient into a phase 2 clinical trial of GLK-302 for the treatment of presbyopia and GLK-301 for the treatment of signs and symptoms of dry eye disease (DED). GLK-302 is the second investigational drug candidate utilizing Glaukos&rsq
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of Brimochol for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-2-vivid-study-of-brimochol-for-the-treatment-of-presbyopia/2480481/Visus Therapeutics reported positive topline results from VIVID, the company’s phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia. All three investigational candidates studied in VIVID achieved the endpoint of 3 lines of improvem
- Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-publication-in-ophthalmology-of-onset-2-phase-3-data-on-tyrvaya-varenicline-solution-nasal-spray/2480446/Oyster Point Pharma announced that results from the multicenter, randomized, double-masked, vehicle-controlled phase 3 clinical trial (The ONSET-2 study) of Tyrvaya Nasal Spray (varenicline solution) have been published in Ophthalmology.1 
- Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meetinghttps://modernod.com/news/nicoxs-ncx-470-dolomites-phase-2-results-in-glaucoma-patients-to-be-presented-at-the-aao-2021-annual-meeting/2480425/Nicox SA announced a poster presentation highlighting responder analyses results from the Dolomites phase 2 clinical trial on NCX 470 in patients with open-angle glaucoma or ocular hypertension at the American Academy of Ophthalmology 2021 Annual Meeting being held from N
- Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopiahttps://modernod.com/news/eyenovia-announces-first-patient-enrolled-in-phase-3-vision-2-trial-of-microline-for-presbyopia/2480400/Eyenovia announced that the first patient has been enrolled in the company’s second Phase 3 clinical trial of MicroLine, its proprietary pilocarpine formulation for temporary improvement in presbyopia, known as VISION-2. “Following the co
- Aldeyra Therapeutics Announces Achievement of Primary Endpoint in Phase 2 Clinical Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-achievement-of-primary-endpoint-in-phase-2-clinical-trial-in-dry-eye-disease/2480392/Aldeyra Therapeutics announced achievement of the primary endpoint of ocular redness in a randomized, double-masked, vehicle-controlled phase 2 clinical trial in patients with dry eye disease. The clinical trial enrolled 158 patients: 80 patients were randomized to receive 0.25% re